Evaluating the risks of clinical research

JAMA

Volumn 304, Issue 13, 2010, Pages 1472-1479

  Rid, Annette ^a,b   Emanuel, Ezekiel J ^a   Wendler, David ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN;

ALLERGIC REACTION; ANXIETY; BLEEDING; CLINICAL RESEARCH; COGNITION; COLON PERFORATION; DECISION MAKING; EMPHYSEMA; GALLBLADDER PERFORATION; HEALTH HAZARD; HEMATOTHORAX; LIVER BIOPSY; PAIN; PATIENT ADVOCACY; PHYSICAL EXAMINATION; PLEURA EFFUSION; PNEUMOTHORAX; PRICK TEST; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RESEARCH ETHICS; RESEARCH SUBJECT; REVIEW; RISK ASSESSMENT; SEPSIS; SKIN TEST; ARTICLE; BIOPSY; ETHICS; HARM REDUCTION; HUMAN; HYPERSENSITIVITY; LIVER DISEASE; MEDICAL RESEARCH; STATISTICAL MODEL;

BIOMEDICAL RESEARCH; BIOPSY; HARM REDUCTION; HUMANS; HYPERSENSITIVITY; LIKELIHOOD FUNCTIONS; LIVER DISEASES; RISK ASSESSMENT; SKIN TESTS;

EID: 77957672482     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1414     Document Type: Review

References (71)

1. Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185(4157):1124-1131.
2. Slovic P. Perception of risk. Science. 1987;236(4799):280-285. (Pubitemid 17242905)
3. Slovic P. The Perception of Risk. London, England: Earthscan Publications; 2000.
4. Weinstein ND. Optimistic biases about personal risks. Science. 1989;246(4935):1232-1233.
5. Shah S, Whittle A, Wilfond B, Gensler G, Wendler D. How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA. 2004;291(4):476-482. (Pubitemid 38129752)
6. Lenk C, Radenbach K, Dahl M, Wiesemann C. Non-therapeutic research with minors. J Med Ethics. 2004;30(1):85-87.
7. Office for Human Research Protections database. http://ohrp.cit.nih.gov/ search/. Accessed January 12, 2010.
8. Department of Health & Human Services Office of the Inspector General. Institutional review boards: a time for reform, June 1998 (publication OEI-01-97-00193). http://oig.hhs.gov/oei/reports/oei-01-97-00193.pdf. Accessed September 10, 2010.
9. Wood A, Grady C, Emanuel EJ. Regional ethics organizations for protection ofhumanresearch participants. Nat Med. 2004;10(12):1283-1288. (Pubitemid 40022703)
10. Department of Health and Human Services. US Code of Federal Regulations, 45 CFR 46; revised 1991. Protection of Human Subjects.
11. Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for biomedical research involving human subjects 2002. http://www.cioms.ch/publications/layout-guide2002.pdf. Accessed April 18, 2009.
12. Wendler D. Protecting subjects who cannot give consent. Hastings Cent Rep. 2005;35(5):37-43.
13. Wendler D. The Ethics of Pediatric Research. New York, NY: Oxford University Press; 2010.
14. London AJ. Two dogmas of research ethics and the integrative approach to human-subjects research. JMed Philos. 2007;32(2):99-116.
15. Miller FG, Joffe S. Limits to research risks. J Med Ethics. 2009;35(7):445-449.
16. Wendler D, Varma S. Minimal risk in pediatric research. J Pediatr. 2006;149(6):855-861.
17. Murray CJ. Quantifying the burden of disease. Bull World Health Organ. 1994;72(3):429-445.
18. Ware JE Jr, Sherbourne CD. The MOS36-item short-form health survey (SF-36). Med Care. 1992;30(6):473-483.
19. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53-72.
20. Erickson P. Evaluation of a population-based measure of quality of life. Qual Life Res. 1998;7(2):101-114.
21. Rosser R, Kind P. A scale of valuations of states of illness. Int J Epidemiol. 1978;7(4):347-358.
22. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001;33(5):375-384.
23. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Pharmacoeconomics. 1995;7(6):490-502.
24. Kaplan RM, Bush JW, Berry CC. Health status index. Med Care. 1979;17(5):501-525.
25. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
26. Murray CJ. Rethinking DALYs. In: Murray CJ, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press; 1996:1-98.
27. National Cancer Institute (NCI). NCI common terminology criteria for adverse events v3.0 (CTCAE), August 9, 2006. http://ctep.info.nih.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed January 20, 2010.
28. Cox EP. The optimal number of response alternatives for a scale. J Mark Res. 1980;17(4):407-422.
29. Preston CC, Colman AM. Optimal number of response categories in rating scales. Acta Psychol (Amst). 2000;104(1):1-15.
30. Miller GA. The magical number seven plus or minus two. Psychol Rev. 1956;63(2):81-97.
31. Feinberg J. The Moral Limits of the Criminal Law: Harm to Others. Vol 1. New York, NY: Oxford University Press; 1984.
32. Levine RJ. Ethics and Regulation of Clinical Research. Baltimore, MD: Urban & Schwarzenberg; 1981.
33. Indian Council of Medical Research. Ethical Guidelines for Biomedical Research on Human Participants. New Delhi, India: Director-General Indian Council of Medical Research; 2006.
34. South African Medical Research Council. Guidelines on Ethics for Medical Research: General Principles, Including Research on Children, Vulnerable Groups, International Collaboration and Epidemiology. Cape Town, South Africa: South African Medical Research Council; 2002.
35. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Tri-Council policy statement: ethical conduct for research involving humans; Ottawa, Canada; 2005. http://www.pre.ethics.gc.ca/policy-politique/tcps- eptc/docs/TCPS%20October%202005-E.pdf. Accessed September 20, 2010.
36. Uganda National Council for Science and Technology. National Guidelines for Research Involving Humans as Research Participants. Kampala, Uganda: UNCST; 2007.
37. Committee on Clinical Research Involving Children. Ethical Conduct of Clinical Research Involving Children. In: Field JJ, Behrman RE, eds. Washington, DC: The National Academies Press; 2004.
38. Nathanson A, Bird S, Dao L, Tam-Sing K. Competitive surfing injuries. Am J Sports Med. 2007;35(1):113-117.
39. Ingram JG, Fields SK, Yard EE, Comstock RD. Epidemiology of knee injuries among boys and girls in US high school athletics. Am J Sports Med. 2008;36(6):1116-1122.
40. Brown J. Amputations: a continuing workplace hazard (originally published January 30, 2003). US Dept of Labor; Bureau of Labor Statistics Web site. http://www.bls.gov/opub/cwc/sh20030114ar01p1.htm. Accessed September 20, 2010.
41. Floyd T. Alpine skiing, snowboarding, and spinal trauma. Arch Orthop Trauma Surg. 2001;121(8):433-436.
42. Wendler D, Belsky L, Thompson KM, Emanuel EJ. Quantifying the federal minimal risk standard. JAMA. 2005;294(7):826-832.
43. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Am J Med. 1985;78(6B):32-37.
44. Arruda E, Pitkäranta A, Witek TJ Jr, Doyle CA, Hayden FG. Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol. 1997;35(11):2864-2868.
45. Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing. J Allergy Clin Immunol. 2004;113(6):1129-1136.
46. Codreanu F, Moneret-Vautrin DA, Morisset M, et al. The risk of systemic reactions to skin prick-tests using food allergens. Eur Ann Allergy Clin Immunol. 2006;38(2):52-54.
47. Devenney I, Fälth-Magnusson K. Skin prick tests may give generalized allergic reactions in infants. Ann Allergy Asthma Immunol. 2000;85(6 pt 1):457-460.
48. Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy. 1993;71(6):557-562.
49. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79(4):660-677.
50. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol. 1993;92(1 pt 1):6-15.
51. Turkeltaub PC, Gergen PJ. The risk of adverse reactions from percutaneous prick-puncture allergen skin testing, venipuncture, and body measurements. J Allergy Clin Immunol. 1989;84(6 pt 1):886-890.
52. Valyasevi MA, Maddox DE, Li JT. Systemic reactions to allergy skin tests. Ann Allergy Asthma Immunol. 1999;83(2):132-136.
53. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495-500.
54. Cadranel JF, Rufat P, Degos F; for the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Practices of liver biopsy in France. Hepatology. 2000;32(3):477-481.
55. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales. Gut. 1995;36(3):437-441.
56. Grant A, Neuberger J; British Society of Gastroenterology. Guidelines on the use of liver biopsy in clinical practice. Gut. 1999;45(suppl 4):IV1-IV11.
57. Greenwald R, Chiprut RO, Schiff ER. Percutaneous aspiration liver biopsy using a large-caliber disposable needle. Am J Dig Dis. 1977;22(12):1109-1114.
58. Malnick S, Melzer E. Routine ultrasound-guided liver biopsy. J Clin Gastroenterol. 2005;39(10):900-903.
59. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990;99(5):1396-1400.
60. Minuk GY, Sutherland LR, Wiseman DA, MacDonald FR, Ding DL. Prospective study of the incidence of ultrasound-detected intrahepatic and subcapsular hematomas in patients randomized to 6 or 24 hours of bed rest after percutaneous liver biopsy. Gastroenterology. 1987;92(2):290-293.
61. Okuda K, Musha H, Nakajima Y, et al. Frequency of intrahepatic arteriovenous fistula as a sequela to percutaneous needle puncture of the liver. Gastroenterology. 1978;74(6):1204-1207.
62. Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology. 1978;74(1):103-106.
63. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. J Hepatol. 1986;2(2):165-173.
64. Van Thiel DH, Gavaler JS, Wright H, Tzakis A. Liver biopsy: its safety and complications as seen at a liver transplant center. Transplantation. 1993;55(5):1087-1090.
65. Finkel AM. Toward less misleading comparisons of uncertain risks. Environ Health Perspect. 1995;103(4):376-385.
66. Andrews CJ, Hassenzahl DM, Johnson BB. Accommodating uncertainty in comparative risk. Risk Anal. 2004;24(5):1323-1335.
67. Starr C. Social benefit versus technological risk. Science. 1969;165(899):1232-1238.
68. Shrader-Frechette KS. Risk and Rationality: Philosophical Foundations for Populist Reforms. Berkeley: University of California Press; 1991.
69. Sunstein C. Risk and Reason. Cambridge, MA: Cambridge University Press; 2002.
70. Fischoff B, Lichtenstein S, Slovic P, Derby SL, Keeney RL. Acceptable Risk. New York, NY: Cambridge University Press; 1981.
71. Hansson SO. Ethical criteria of risk acceptance. Erkenntnis. 2003;59:291-309. doi:10.1023/A:1026005915919.